Saturday

17th Nov 2018

Opinion

Intellectual property protection - the cure for Europe's ills

  • The Commission risks giving a 'sweetheart' deal for generic drug companies - which does nothing for research and development (Photo: www.freeimages.co.uk)

Like it or not, Europe is getting older, thanks to a combination of falling birthrates and increasing lifespans: from 2006 to 2016, the proportion of European Union citizens aged 65 and up increased from 16.8 percent to 19.2 percent, while the share of under-15s slipped from 16 percent to 15.6 percent.

By 2080, three in ten Europeans will be 65 or older.

Read and decide

Join EUobserver today

Support quality EU news

Get instant access to all articles — and 18 year's of archives. 30 days free trial.

... or join as a group

Our ageing population isn't a bad thing.

Most people would probably agree it's good to live longer, while smaller family sizes are associated with a higher standard of living and social mobility.

Nevertheless, it presents a looming health challenge in the form of more serious and chronic diseases, including cancer, diabetes, hypertension, and dementia.

Chronic diseases already account for the lion's share of health expenditures, at four-fifths of the European total, in addition to costing an estimated €115bn per year in lost productivity from deaths among working adults.

So it is puzzling to see Europe's governing bodies considering measures that would undermine the incentives for scientific innovation needed to treat these illnesses, along with countless other future remedies – all in the name of marginal cost savings that can undoubtedly be found elsewhere.

For almost two decades, Europe has used a system of intellectual property protections and incentives to encourage research into treatments for a range of diseases, for example by guaranteeing longer market exclusivity for drugs to treat rare conditions, or granting extended patent protection that partially compensates innovators for the long regulatory approval process involved in bringing a new medicine to market.

The system works

Thanks to R&D incentives, the number of new treatments for rare diseases approved by the European Medicines Agency under the program soared from just eight in 2000 to 136 today.

But protections are needed now more than ever. Over the years, the science of new medicines development has become more difficult, and the scope, complexity and cost of conducting clinical trials has increased dramatically.

However with national budgets under pressure and healthcare costs increasing, in June 2016 the European Commission began considering the possibility of rolling back medical research incentives, on the faulty assumption they are somehow driving higher drug prices.

But not only is that premise flawed – the proposed fix will do nothing to benefit ordinary health consumers.

In fact, Europe is not spending dramatically more on drugs, and only modest increases are forecast in coming years.

According to the World Health Organization, retail expenditures on medicines in the EU-15 decreased steadily as a proportion of total healthcare spending from 2004 to 2014, while per capita expenditures on drugs remained stable.

Looking to the future, European drug spending is predicted to grow at a compound annual rate of just one percent to four percent from 2016-2021, roughly in line with the predicated rate of inflation for Europe over the same period.

As these numbers indicate, drug costs have not played a significant role in rising overall healthcare expenditures, which grew from an average of 8.8 percent of GDP to 9.9 percent across the EU from 2005-2015.

Rather, increasing healthcare costs are largely the result – in Europe as in the rest of the developed world – of growing demand for long-term care (expected to double to 3.6 percent of GDP by 2060), as well as new technology and stagnant productivity.

The researchers who discover and develop new treatments and cures may be easy political targets.

Drug prices aren't the problem

But since drug prices aren't actually the problem, it's worth asking what's really behind the move to weaken incentives.

The answer might lie with a proposal to limit extended protections Europe provides for some medicines. According to the European Commission's own background paper, the proposal is intended to enable generic drug makers on the continent to begin selling copies of these medicines overseas during the period of extended protection.

This might be a sweetheart deal for generic drug companies – which spend virtually nothing on R&D for new drugs. But it would do nothing for European patients or national health systems, while putting the kind of R&D jobs the EU needs more of at risk across the continent.

The European commission should recalibrate its approach. We should strive to encourage innovation, not undermine it. Our market-based system has yielded practically all medical advances to date, and with an ageing population beset by chronic disease, we urgently need better treatments and cures.

Pietro Paganini is president of Italian think tank Competere, serves as an adjunct professor at John Cabot University in Rome and Fox School of Business at Temple University of Philadelphia, and a columnist for the Italian daily newspaper, La Stampa.

Why are our medicines so expensive?

The EU should be promoting open innovation in upcoming trade talks with India and should work to bring down the prices of essential medicines, both abroad and within its borders.

US steps in to clean up Cyprus

Cyprus has overlooked undertakings on bank probity made to the EU in the context of the 2013 bailout - but it might prove harder to get the US off its back.

Macron's 'European army': why is everyone talking about it?

Few people commented on one key point in Macron's statement: he did not justify the idea of a European army by the need to intervene in Africa, which would have been France's traditional approach. Instead, he invoked the Russian threat,

News in Brief

  1. US warns EU banks and firms against trading with Iran
  2. Merkel urged Romania not to move embassy to Jerusalem
  3. Protesters call for Czech leader to step down
  4. Former German chancellor labelled 'enemy' of Ukraine
  5. French lead opposition to Brexit deal on fisheries
  6. Private accounts of Danske Bank employees investigated
  7. UK's May defends Brexit deal to MPs, after ministers resign
  8. Brexit MP calls for 'no confidence' vote on May

Why 'Spitzenkandidat' is probably here to stay

The power of the parliament to 'appoint' the president of the EU Commission is new, highly-contested - and not universally understood. In fact, even some of the lead candidates to replace Jean-Claude Juncker are against it.

Stakeholders' Highlights

  1. NORDIC COUNCIL OF MINISTERSTheresa May: “We will not be turning our backs on the Nordic region”
  2. International Partnership for Human RightsOpen letter to Emmanuel Macron ahead of Uzbek president's visit
  3. International Partnership for Human RightsRaising key human rights concerns during visit of Turkmenistan's foreign minister
  4. NORDIC COUNCIL OF MINISTERSState of the Nordic Region presented in Brussels
  5. NORDIC COUNCIL OF MINISTERSThe vital bioeconomy. New issue of “Sustainable Growth the Nordic Way” out now
  6. NORDIC COUNCIL OF MINISTERSThe Nordic gender effect goes international
  7. NORDIC COUNCIL OF MINISTERSPaula Lehtomaki from Finland elected as the Council's first female Secretary General
  8. NORDIC COUNCIL OF MINISTERSNordic design sets the stage at COP24, running a competition for sustainable chairs.
  9. Counter BalanceIn Kenya, a motorway funded by the European Investment Bank runs over roadside dwellers
  10. ACCACompany Law Package: Making the Best of Digital and Cross Border Mobility,
  11. International Partnership for Human RightsCivil Society Worried About Shortcomings in EU-Kyrgyzstan Human Rights Dialogue
  12. UNESDAThe European Soft Drinks Industry Supports over 1.7 Million Jobs

Latest News

  1. Brexit dominates EU affairs This WEEK
  2. How the EU commission got tunnel vision on self-driving cars
  3. No-confidence calls against May put Brexit deal in doubt
  4. Key points of the Brexit deal (if it ever comes into effect)
  5. Romania heaps scorn on 'revolting' EU criticism
  6. US steps in to clean up Cyprus
  7. 'Decisive progress' on Brexit as British cabinet backs deal
  8. Asylum for Macedonia's ex-PM puts Orban on spot

Stakeholders' Highlights

  1. Mission of China to the EUJointly Building Belt and Road Initiative Leads to a Better Future for All
  2. International Partnership for Human RightsCivil society asks PACE to appoint Rapporteur to probe issue of political prisoners in Azerbaijan
  3. ACCASocial Mobility – How Can We Increase Opportunities Through Training and Education?
  4. Nordic Council of MinistersEnergy Solutions for a Greener Tomorrow
  5. UNICEFWhat Kind of Europe Do Children Want? Unicef & Eurochild Launch Survey on the Europe Kids Want
  6. Nordic Council of MinistersNordic Countries Take a Stand for Climate-Smart Energy Solutions
  7. Mission of China to the EUChina: Work Together for a Better Globalisation
  8. Nordic Council of MinistersNordics Could Be First Carbon-Negative Region in World
  9. European Federation of Allergy and AirwaysLife Is Possible for Patients with Severe Asthma
  10. PKEE - Polish Energy AssociationCommon-Sense Approach Needed for EU Energy Reform
  11. Nordic Council of MinistersNordic Region to Lead in Developing and Rolling Out 5G Network
  12. Mission of China to the EUChina-EU Economic and Trade Relations Enjoy a Bright Future

Join EUobserver

Support quality EU news

Join us